Evaluation of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis

Primary tabs

NEWS
Evaluation of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis

Rheumatoid arthritis affects the joints of the hands, feet, wrists, elbows, knees, and ankles. About 1.5 million people in the United States have rheumatoid arthritis (RA). Nearly three times as many females have the disease as men. In women, RA most generally occurs between ages 30 and 60. In the male, it often happens later in life.

This observational, non-randomized study aimed to clarify the unknown effects of switching oral bisphosphonates (BPs) to denosumab (DMAb) or daily teriparatide (TPTD) in subjects with rheumatoid arthritis (RA). The characteristics of the 194 female patients involved in the evaluation were 183 postmenopausal, age 65.9 years. Moreover, lumbar spine (LS) T score −1.8, femoral neck (FN) T score −2.3, dose and rate of administered oral prednisolone (3.6 mg/day) 75.8%, and prior BP therapy duration 40.0 months. The subjects were earmarked to (1) the BP-continue assemblage (n = 80), (2) the switch-to-DMAb assemblage (n = 74), or (3) the switch-to-TPTD assemblage (n = 40). The rise in bone mineral density (BMD) was consequently higher in the switch-to-DMAb assemblage than in the BP-continue assemblage (LS 5.2 vs 2.3%, P < 0.01; FN 3.8 vs 0.0%, P < 0.01) and in the switch-to-TPTD assemblage than in the BP-continue assemblage (LS 9.0 vs 2.3%, P < 0.001; FN 4.9 vs 0.0%, P < 0.01) after 18 months. Moreover, the switch-to-TPTD group noted trabecular bone score (TBS) (2.1 vs −0.7%; P < 0.05) rise and a greater LS BMD (P < 0.05) than the switch-to-DMAb group. Clinical fracture occurrence throughout the period was 8.8% in the BP-continue group, 4.1% in the switch-to-DMAb assemblage, and 2.5% in the switch-to-TPTD group.

Both the switch-to-DMAb group and the switch-to-TPTD group noted consequent increases in LS and FN BMD, and the switch-to-TPTD group exhibited a noticeable improvement in TBS corresponded to the BP-continue group at 18 months. Switching BPs to DMAb or TPTD in woman RA may produce some useful osteoporosis treatment prospects. (9-7-1994 & 4:15 am).

Source:

Journal of Bone and Mineral Metabolism

Link to the source:

https://link.springer.com/article/10.1007%2Fs00774-017-0861-4

Original title of the article:

Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis

Authors:

Antoni; F. et al.

SearchTags: 
Therapeutic, Bisphosphonates, Denosumab, Teriparatide, Rheumatoid arthritis, Hands, Feet, Wrists, Non-randomized, Oral
Log in or register to post comments